Mirae Asset Global Investments Co. Ltd. Decreases Stake in Sight Sciences, Inc. (NASDAQ:SGHT)

Mirae Asset Global Investments Co. Ltd. lessened its holdings in shares of Sight Sciences, Inc. (NASDAQ:SGHT) by 33.4% in the 4th quarter, Holdings Channel reports. The fund owned 17,547 shares of the company’s stock after selling 8,787 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Sight Sciences were worth $91,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Boston Partners boosted its position in shares of Sight Sciences by 3.1% during the 3rd quarter. Boston Partners now owns 331,776 shares of the company’s stock valued at $1,117,000 after acquiring an additional 9,919 shares during the last quarter. Swiss National Bank boosted its holdings in Sight Sciences by 19.5% in the 3rd quarter. Swiss National Bank now owns 69,314 shares of the company’s stock valued at $234,000 after purchasing an additional 11,300 shares during the last quarter. First Eagle Investment Management LLC grew its stake in shares of Sight Sciences by 45.6% in the 3rd quarter. First Eagle Investment Management LLC now owns 587,297 shares of the company’s stock valued at $1,979,000 after buying an additional 183,912 shares during the period. Finally, Federated Hermes Inc. increased its holdings in shares of Sight Sciences by 100.0% during the 3rd quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $202,000 after buying an additional 30,000 shares during the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analyst Ratings Changes

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research report on Wednesday, April 10th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $4.60.

Insider Activity at Sight Sciences

In other Sight Sciences news, CFO Alison Bauerlein sold 10,123 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total value of $51,424.84. Following the transaction, the chief financial officer now directly owns 426,248 shares in the company, valued at $2,165,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Paul Badawi sold 12,571 shares of the company’s stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $63,860.68. Following the completion of the sale, the chief executive officer now owns 5,750,729 shares in the company, valued at $29,213,703.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Alison Bauerlein sold 10,123 shares of Sight Sciences stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total transaction of $51,424.84. Following the completion of the transaction, the chief financial officer now owns 426,248 shares in the company, valued at $2,165,339.84. The disclosure for this sale can be found here. Insiders sold 34,129 shares of company stock valued at $173,375 over the last three months. 27.10% of the stock is owned by corporate insiders.

Sight Sciences Stock Up 2.7 %

Shares of NASDAQ:SGHT opened at $5.28 on Monday. Sight Sciences, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $11.20. The firm’s 50 day moving average price is $4.97 and its 200 day moving average price is $4.13. The company has a quick ratio of 12.65, a current ratio of 13.29 and a debt-to-equity ratio of 0.26. The stock has a market cap of $261.62 million, a price-to-earnings ratio of -4.63 and a beta of 2.83.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.13. Sight Sciences had a negative return on equity of 41.94% and a negative net margin of 68.53%. The business had revenue of $18.75 million during the quarter, compared to analysts’ expectations of $18.70 million. During the same period in the prior year, the firm posted ($0.35) EPS. As a group, equities research analysts predict that Sight Sciences, Inc. will post -1.04 earnings per share for the current fiscal year.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.